07 December 2023 : Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz
1ACDEF*, Anna Dańska-Bidzińska 2ABDEG, Małgorzata Fuksiewicz 1BCDE, Anna Nasierowska-Guttmejer 3BC, Dorota Raczkiewicz 4C, Mariusz Gujski 5BEF, Szymon Piątek 6B, Mariusz Bidziński 6AEG
DOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 4 The histopathological type of tumor, number of patients who died/number of all patients, the percentage of deaths, and the survival time in months.
| Histopathological type | Death/all patients (%) | Survival (months) min–max; median |
|---|---|---|
| Carcinosarcoma | 16/18 (89) | 7–165; 16 |
| Leiomyosarcoma | 9/13 (69) | 6–141; 36 |
| High grade ESS | 6/10 (60) | 13–138; 21 |
| Low grade ESS | 0/4 (0) | 101–149; 138 |
| Adenosarcoma | 1/5 (20) | 69–157; 119 |
| Rhabdomyosarcoma | 0/1 (0) | 142 |
| Solitary fibrous tumour | 0/1 (0) | 138 |